For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Vyndamax and Tafamidis meglumine represents a significant breakthrough . These innovative therapies preserve the transthyretin protein, slowing its harmful build-up and reducing the impact of the condition . Patients are now seeing im